Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Patent
1995-06-01
1998-07-07
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
4241781, 4241431, 4241791, 424 9321, 4241381, 4241451, 4241811, 4241831, 5303917, 5303872, 53038822, 53038873, A61K 5110, A61K 35395, C07K 1600
Patent
active
057764271
ABSTRACT:
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
Aoyagi, "Distribution of Plasma Fibronectin in the Metastatic Lesion of Cancer: Experimental Study by Autoradiography," Thrombosis Research, 49:265-75, 1988 Without Month.
Balza et al., "Production and Characterization of Monoclonal Antibodies Specific for Different Epitopes of Human Tenascin," FEBS 332(1,2):39-43, 1993 Without Month.
Bjorndahl, et al., "Human T Cell Activation: Differential Response to Anti-CD28 As Compared to Anti-CD3 Monoclonal Antibodies," Eur. J. Immunol., 19:881-87, 1989 Without Month.
Blanchard, et al., "Infiltration of Interleukin-2-Inducible Killer Cells in Ascitic Fluid and Pleural Effusions of Advanced Cancer Patients," Cancer Research, 48:6321-27, 1988 Without Month.
Bohlen, et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies," Cancer Research, 53:4310-14, 1993 Without Month.
Borsi, et al., "Expression of Different Tenascin Isoforms in Normal, Hyperplastic and Neoplastic Human Breast Tissues," Int. J. Cancer, 52:688-92, 1992 Without Month.
Boyer, et al., "Differential Induction by Interferons of Major Histocompatibility Complex-Encoded and Non-Major Histocompatibility Complex-Encoded Antigens in Human Breast and Ovarian Carcinoma Cell Lines," Cancer Research, 49:2928-34, 1989 Without Month.
Burton-Wurster, et al., "Expression of the Ed B Fibronectin Isoform in Adult Human Articular Cartilage," Biochemical and Biophysical Research Communication 165(2): 782-87, 1989 w/o Month.
Collins, et al., "Immune Interferon Activates Multiple Class II Major Histocompatibility Complex Genes and the Associated Invariant Chain Gene in Human Endothelial Cells and Dermal Fibroblasts," Proc. Natl. Acad. Sci. USA, 81:4917-21, 1984 w/o Month.
Carnemolla et al., "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors," The Journal of Cell Biology, 108:1139-48, 1989 w/o Month.
Carnemolla et al., "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Modifications that Unmask a Cryptic Sequence," The Journal of Biological Chemistry, 267(34):24589:92, 1992 w/o Month.
Carnemolla, et al., "Phage Antibodies with Pan-Species Recognition of the Oncofoetal Angiogenesis Marker Fibronectin ED-B Domain," Int. J. Cancer 68:397-405, 1996 w/o Month.
Castellani, et al., "The Fibronectin Isoform Containing the ED-B Oncofoetal Domain: A Marker of Angiogenesis," Int. J. Cancer, 59:612-18, 1994 w/o Month.
Conforti, et al., "Human Endothelial Cells Express Integrin Receptors on the Luminal Aspect of Their Membrane," Blood 80(2):437-46, 1992 w/o Month.
Dillman, "Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine, 111(7) 592-600, 1989 w/o Month.
Farnoud, et al., "Fibronectin Isoforms Are Differentially Expressed in Normal and Adenomatous Human Anterior Pituitaries," Int. J. Cancer, 61:27-34, 1995 w/o Month.
Garin-Chesa, et al., "Cell Surface Glycoprotein of Reactive Stromal Fibroblasts As A Potential Antibody Target in Human Epithelial Cancers," Proc. Natl. Acad. Sci. USA, 87:7235-39, 1990 w/o Month.
Groenewegen, et al., "Lymphokine Dependence of In Vivo Expression of MHC Class II Antigens by Endothelium," Nature, 316:361-63, 1985 w/o Month.
Harris and Emery, "Therapeutic Antibodies--The Coming of Age," Btech, 11:42-44, 1993 w/o Month.
June, et al., "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression," Molecular and Cellular Biology 7(12):4473-81, 1987 w/o Month.
Kaczmarek, et al., "Distribution of Oncofetal Fibronectin Isoforms in Normal Hyperplastic and Neoplastic Human Breast Tissues," Int. J. Cancer, 58:11-16, 1994 w/o Month.
Koulova et al., "The CD28 Ligand B7/BB1 Provides Costimulatory Signal for Alloactivation of CD4.sup.+ T Cells," J. Exp. Med. 173:759-62, 1991 w/o Month.
Kurosawa, et al., "Early Appearance and Activation of Natural Killer Cells in Tumor-Infiltrating Lymphoid Cells During Tumor Development," Eur. J. Immunol. 23:1029-33, 1993 w/o Month.
Lampugnani, et al., "The Role of Integrins in the Maintenance of Endothelial Monolayer Integrity," The Journal of Cell Biology, 112(3):479-90, 1991 w/o Month.
Linnala, et al., "Human Amnion Epithelial Cells Assemble Tenascins and Three Fibronectin Isoforms in the Extracellular Matrix," FEBS, 314(1,2):74-78, 1993 w/o Month.
Maeda, et al., "Production and Characterization of Tumor Infiltrating Lymphocyte Clones Derived from B16-F10 Murine Melanoma," The Journal of Investigative Dermatology 97(2):183-89, 1991 w/o Month.
Natali, et al., "Comparative Analysis of the Expression of the Extracellular Matrix Protein Tenascin in Normal Human Fetal, Adult and Tumor Tissues," Int. J. Cancer, 47:811-16, 1991 w/o Month.
Oyama, et al., "Coordinate Oncodevelopmental Modulation of Alternative Splicing of Fibronectin Pre-Messenger RNA at ED-A, ED-B and CS1 Regions in Human Liver Tumors," Cancer Research 53:2005-11, 1993 w/o Month.
Peters, et al., "Expression of the Alternatively Spliced EIIIB Segment of Fibronectin," Cell Adhesion and Communication, 3:67-89, 1995 w/o Month.
Pober et al., "Ia Expression by Vascular Endothelium Is Indcuible by Activated T Cells and by Human .gamma. Interferon," J. Exp Med. 157: 1339-53, 1983 w/o Month.
Pohl, et al., "CD30-Antigen-Specific Targeting and Activation of T Cells via Murine Bispecific Monoclonal Antibodies Against CD3 and CD28: Potential Use for the Treatment of Hodgkin's Lymphoma," Int. J. Cancer, 54:820-27, 1993 w/o Month.
Renner, et al., "Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells," Science, 264:833-35, 1994 w/o Month.
Rettig, et al., "Cell-Surface Glycoproteins of Human Sarcomas: Differential Expression in Normal and Malignant Tissues and Cultured Cells," Proc. Natl. Acad. Sci. USA, 85:3110-14, 1988 w/o Month.
Rettig, et al., Identification of Endosialin, A Cell Surface Glycoprotein of Vascular Endothelial Cells in Human Cancer, Proc. Natl. Acad. Sci. USA, 89:10832-36, 1992 w/o Month.
Rosenberg, Steven, "Lymphokine-Activated Killer Cells: A New Approach to Immunotherapy of Cancer," JNCI 75(4):595-603, 1985 w/o Month.
Rosenberg, et al., "Observations of the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer," The New England Journal of Medicine, 313(23):1485-92, 1985 w/o Month.
Ruiter, et al., "Monoclonal Antibody-Defined Human Endothelial Antigens as Vascular Markers," J. Investigative Dermatol., 93(2):25S-32S, 1989 w/o Month.
Saiki et al., "Anti-metastatic and Anti-invasive Effects of Polymeric Arg-Gly-Asp (RGD) Peptide, Poly(RGD), and Its Analogues," Jpn. J. Cancer Res. 81:660-67, 1990 w/o Month.
Saiki et al., "Inhibition of Tumor Angiogenesis by a Synthetic Cell-Adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD)," Jpn. J. Cancer Res. 81:668-75, 1990 w/o Month.
Schlingemann, et al., "Differential Expression of Markers for Endothelial Cells, Pericytes, and Basal Lamina in the Microvasculature of Tumors and Granulation Tissue," Am. J. Pathol. 138(6):1335-47, 1991 w/o Month.
Schwarzbauer, "Alternativ
Burrows Francis J.
Thorpe Philip E.
Board of Regents , The University of Texas System
Hartley Michael G.
Kight John
LandOfFree
Methods for targeting the vasculature of solid tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for targeting the vasculature of solid tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for targeting the vasculature of solid tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1202380